2020 Press Releases 2024 2023 2022 2021 2020 Portfolio Companies New Leaf Portfolio Companies ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERINGJanuary 7, 2021 HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK January 6, 2021 HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS January 4, 2021 HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS January 4, 2021 Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 StudyDecember 21, 2020 Kyruus and HealthSparq Come Together to Transform Care Navigation Through Novel Payer-Provider Collaboration December 17, 2020 Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock December 14, 2020 Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110December 14, 2020 Kit Check Launches Streamlined Mobile Pharmacy to Boost EfficiencyDecember 8, 2020 Kyruus Named Winner of the Powerhouse Healthcare Company Category at New England Venture Capital Association’s 2020 NEVY AwardsDecember 8, 2020 HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMSDecember 8, 2020 Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program December 8, 2020 Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal TumorNovember 30, 2020 Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNovember 30, 2020 First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual MeetingNovember 13, 2020 Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular DystrophyNovember 11, 2020 Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingNovember 11, 2020 Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingNovember 11, 2020 Study: Telehealth Achieves Nearly 90% Customer SatisfactionOctober 29, 2020 Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option October 26, 2020 Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress DisorderOctober 19, 2020 Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins October 14, 2020 TigerConnect Closes $45M Series D To Meet Soaring DemandOctober 8, 2020 Kit Check and Sandoz Collaborate to Launch RFID-tagged Generic Injectables in October 2020October 1, 2020 Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia September 28, 2020 Kit Check Extends Partnership with Premier Inc. in Multi-Year Contract to Further Advance Pharmacy Visibility with Diversion Detection Software and Medication ManagementSeptember 1, 2020 CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative DiseaseSeptember 15, 2020 Adventist Health Enhances Online Access for Both New and Existing Patients with Kyruus and Cerner Collaboration September 15, 2020 Saniona successfully raises USD 65 million (approximately SEK 567 million) in a directed issue of sharesSeptember 14, 2020 TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call SchedulingSeptember 1, 2020 Sanofi to acquire Principia BiopharmaAugust 17, 2020 ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIOAugust 10, 2020 ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus InfectionAugust 4, 2020 Breztri Aerosphere approved in the US for the maintenance treatment of COPD July 24, 2020 Glympse Bio Announces $46.7 Million Series B Financing July 15, 2020 KLAS Rates TigerConnect Among Top Advanced Clinical Communication Platforms July 8, 2020 Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules June 30, 2020 Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract InfectionsJune 29, 2020 Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisJune 23, 2020 Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisJune 23, 2020 BrightInsight Raises $40M in Series B Funding to Cement our Position as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech June 23, 2020 Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder June 18, 2020 Inspira Health Enables More Streamlined and Seamless Access to Care with Kyruus June 16, 2020 New Research Sheds Light on Intentional Non-adherence in Clinical TrialsJune 15, 2020 Principia Announces Positive Data from its Phase 2 Part B Trial in PemphigusJune 12, 2020 Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialJune 12, 2020 Kyruus Secures $30 Million Investment from Francisco Partners June 10, 2020 Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study June 8, 2020 Neurana Pharmaceuticals Announces Publication of Driving Study May 13, 2020 Kit Check Announces New Sanitization Feature and Medication Tagging Milestone May 4, 2020 Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020May 19, 2020 FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal TumorMay 15, 2020 BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases May 6, 2020 HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA April 27, 2020 TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19 April 16, 2020 BrightInsight Named 2019 Google Cloud Technology Partner of the Year for the Healthcare Industry for Second Year in Row April 6, 2020 Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)March 31, 2020 BrightInsight Announces Global Digital Health Partnership with AstraZeneca March 25, 2020 TigerConnect extends patient communication platform, tools during coronavirus pandemic March 13, 2020 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock February 19, 2020 Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors February 12, 2020 Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report January 31, 2020 Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease January 30, 2020 Key customer wins, rapidly growing customer base, and bold product vision accelerate TigerConnect’s role as a force of change for Healthcare collaboration January 29, 2020 Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors January 17, 2020 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 MilestonesJanuary 13, 2020 Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease January 10, 2020 Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated DiseasesJanuary 7, 2020